Core Viewpoint - The stock of Hansai Aitai-B (03378) has dropped over 13%, reaching a new low of 15.05 HKD, which is more than a 50% decline from its IPO price of 32 HKD [1] Company Overview - Hansai Aitai is a biotechnology company specializing in structural biology, translational medicine, and clinical development, with proprietary core technologies and extensive experience [1] - The company has three clinical-stage candidates in the oncology field and seven preclinical candidates under research [1] - The core product, HX009, is a self-developed dual-function antibody fusion protein targeting PD-1 (an immune checkpoint receptor) and SIRPα [1] Financial Performance - The company reported losses of 85.16 million HKD, 117 million HKD, and 87.44 million HKD for the first eight months of 2023, 2024, and 2025, respectively [1] - As of October 31, 2025, the company had cash and cash equivalents amounting to 133 million HKD, with total current liabilities of 220 million HKD [1]
翰思艾泰-B跌超13% 较招股价已腰斩 总市值约20亿港元